Related Experiment Video

Updated: Nov 10, 2025

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.4K

Emerging Medical Treatment for Hypertrophic Cardiomyopathy

Alessia Argirò1, Mattia Zampieri1, Martina Berteotti1

  • 1Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy.

Journal of Clinical Medicine
|April 3, 2021
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) treatments focus on reducing left ventricular outflow tract (LVOT) obstruction. New cardiac myosin inhibitors and surgical options offer promising therapeutic strategies for managing HCM symptoms.

Area of Science:

  • Cardiology
  • Molecular Medicine
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common heart muscle disease causing unexplained left ventricular hypertrophy.
  • Left ventricular outflow tract (LVOT) obstruction is a primary cause of disabling symptoms in HCM patients.
  • Myocardial hypercontractility is a key factor contributing to LVOT obstruction.

Purpose of the Study:

  • To review current treatment modalities for HCM.
  • To discuss emerging therapeutic opportunities for HCM.
  • To focus on novel cardiac myosin inhibitors and surgical/interventional approaches.

Main Methods:

  • Literature review of current and emerging HCM treatments.
  • Analysis of existing drugs and novel allosteric myosin inhibitors (Mavacamten, CK-274).
  • Discussion of surgical and interventional strategies targeting anatomical abnormalities.

Main Results:

  • Current treatments include surgery for anatomical issues and drugs to reduce hypercontractility.
  • Novel allosteric myosin inhibitors like Mavacamten and CK-274 directly target hypercontractility.
  • Emerging surgical and interventional techniques are also being developed.

Conclusions:

  • HCM management involves addressing both anatomical and functional abnormalities.
  • Allosteric myosin inhibitors represent a promising new drug class for HCM.
  • A combination of pharmacological, surgical, and interventional approaches may optimize HCM treatment.

Keywords:
hypertrophic cardiomyopathyleft ventricular outflow tract obstructionmavacamtenseptal reduction therapy

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.6K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
106
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
124
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
129
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
58
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
172
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
73